Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Anshen Buxin Liuwei Pill
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cardiac Neurosis
1 trial -
Anti-Platelet Drugs
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Unstable Angina
3 trials -
Aspirin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Coronary Syndrome
1 trial -
Aspirin + Clopidogrel + Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
Atomoxetine 80mg combined with oxybutynin 5mg
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obstructive Sleep Apnea of Adult
1 trial -
Baricitinib 4 MG
Chinese University of Hong Kong
Rheumatoid Arthritis
1 trial -
Berberine plus lifestyle intervention
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Obesity
1 trial -
Bisoprolol
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypertension
1 trial -
Bortezomib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
WaldenstrΓΆm Macroglobulinemia
1 trial -
Bortezomib,Pirarubicin,Dexamethasone
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
Brivudine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Herpes Zoster
1 trial -
Brucea javanica oil emulsion injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
Budesonide-Surfactant
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Premature Infants
1 trial -
COVAX
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19 Pneumonia
1 trial -
Camrelizumab + chemotherapy+Thalidomide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Chinese Herb Huang-Chi-Wu-Wu-Tang
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Intracranial Arterial Stenosis
1 trial -
Chloroprocaine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anesthesia
1 trial -
Cinacalcet HCl
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hyperparathyroidism; Secondary, Renal
1 trial -
Citrate anticoagulation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sepsis
1 trial -
Clopidogrel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
Colchicine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
In-stent Restenosis
1 trial -
Colla corii asini
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thalassemia
1 trial -
Colquhounia Root Tablet
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rheumatoid Arthritis
1 trial -
Conventional therapy + S (+)-Ketamine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
S-ketamine
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources